A randomised, double blind trial to assess the morphological and biological effects with Arimidex [anastrozole], compared to placebo when used as neoadjuvant treatment for patients with endometrial cancer.
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Anastrozole (Primary)
- Indications Endometrial cancer
- Focus Pharmacodynamics
- 13 Aug 2009 Planned number of patients changed from 60 to 170 and actual end date (31 Jul 2006) added as reported by ISRCTN: Current Controlled Trials.
- 10 Feb 2006 New trial record.